Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

Indiana's workforce is feeling pressure to return to the office, but a good portion of employees still like hybrid work. Is ...

In 2021, the FDA approved a new insulin drug ... manufacturers for lower drug prices and incentivizing consumers to use ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Simply sign up to the Pharmaceuticals sector myFT Digest ... “There’s a lot of good science that got started in the 2021-22 period and is struggling to get funded, so hopefully at JPMorgan ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Excerpts from recent editorials in the United States and abroad: ___ Jan. 26 The Washington Post on Trump's “energy emergency” Oil and gas production in the United States is hitting record highs, ...

If you are Eli Lilly or Pfizer and you're trying to find ... a platform to connect healthcare professionals to help pharmaceutical, biotech and medical device companies develop drugs and devices.